We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+1.17%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$47.1B
AUM Growth
-$899M
(-1.9%)
Cap. Flow
-$982M
Cap. Flow
% of AUM
-2.08%
Top 10 Holdings %
Top 10 Hldgs %
35.43%
Holding
967
New
122
Increased
219
Reduced
464
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$250M |
| 2 |
Starbucks
SBUX
|
+$152M |
| 3 |
CERN
Cerner Corp
CERN
|
+$122M |
| 4 |
Colgate-Palmolive
CL
|
+$87.1M |
| 5 |
Procter & Gamble
PG
|
+$77.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$456M |
| 2 |
Cisco
CSCO
|
+$392M |
| 3 |
Analog Devices
ADI
|
+$151M |
| 4 |
United Parcel Service
UPS
|
+$148M |
| 5 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$89.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.05% |
| 2 | Consumer Discretionary | 15.92% |
| 3 | Financials | 12.69% |
| 4 | Healthcare | 12.47% |
| 5 | Communication Services | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Insulet
PODD
$9.79B
| $36.6M | 0.08% |
422,326
-128,159
| -23% | -$9.96M |
|
102
Blackbaud
BLKB
$2.08B
| $36.5M | 0.08% |
358,558
-10,977
| -3% | -$1.09M |
|
103
Hilton Worldwide
HLT
$71.5B
| $36.4M | 0.08% |
462,328
-25,015
| -5% | -$2.05M |
|
|
QVCGA
104
DELISTED
QVC Group Inc Series A
QVCGA
| $36.4M | 0.08% |
29,771
-6,540
| -18% | -$8.59M |
|
105
Home BancShares
HOMB
$6.18B
| $35.8M | 0.08% |
1,569,677
-134,026
| -8% | -$3.21M |
|
106
Mettler-Toledo International
MTD
$28.6B
| $35.6M | 0.08% |
61,944
-271
| -0.4% | -$170K |
|
107
Reinsurance Group of America
RGA
$16.1B
| $35.5M | 0.08% |
230,751
-20,104
| -8% | -$3.16M |
|
108
Eli Lilly
LLY
$1.06T
| $35.4M | 0.08% |
457,938
-5,227
| -1% | -$421K |
|
109
Pinnacle Financial Partners Inc
PNFP
$15.8B
| $35.3M | 0.07% |
549,136
-22,300
| -4% | -$1.46M |
|
110
Hexcel
HXL
$7.82B
| $34.9M | 0.07% |
540,501
-16,545
| -3% | -$1.09M |
|
111
Silicon Laboratories
SLAB
$7.23B
| $34.8M | 0.07% |
387,576
-12,055
| -3% | -$1.14M |
|
|
GLIBA
112
DELISTED
GCI Liberty, Inc. Class A Common Stock (DE)
GLIBA
| $34.6M | 0.07% |
+655,410
| New | +$34.4M |
|
113
Penumbra
PEN
$12.8B
| $34.1M | 0.07% |
294,888
+3,349
| +1% | +$346K |
|
|
PDCE
114
DELISTED
PDC Energy, Inc.
PDCE
| $34M | 0.07% |
694,117
-60,464
| -8% | -$3.18M |
|
115
Q2 Holdings
QTWO
$3.92B
| $33.7M | 0.07% |
740,746
+45,871
| +7% | +$1.98M |
|
116
FIVE9
FIVN
$2.54B
| $33.7M | 0.07% |
1,130,995
+343,399
| +44% | +$9.41M |
|
117
Conduent
CNDT
$264M
| $33.6M | 0.07% |
1,800,031
+15,403
| +0.9% | +$271K |
|
118
Columbia Sportswear
COLM
$2.94B
| $33.5M | 0.07% |
437,700
-13,932
| -3% | -$1.05M |
|
119
SiteOne Landscape Supply
SITE
$4.53B
| $33.3M | 0.07% |
432,470
-14,521
| -3% | -$1.07M |
|
120
Albany International
AIN
$1.78B
| $33.3M | 0.07% |
531,321
+22,886
| +5% | +$1.46M |
|
|
OPLN
121
Openlane
OPLN
$4.54B
| $33.1M | 0.07% |
1,615,115
-31,039
| -2% | -$626K |
|
122
Ollie's Bargain Outlet
OLLI
$4.94B
| $32M | 0.07% |
530,019
-18,766
| -3% | -$1.07M |
|
123
Citigroup
C
$226B
| $31.8M | 0.07% |
471,556
-74,136
| -14% | -$5.57M |
|
|
CALD
124
DELISTED
Callidus Software, Inc.
CALD
| $31.3M | 0.07% |
870,944
-437,640
| -33% | -$15M |
|
125
Cogent Communications
CCOI
$508M
| $31.2M | 0.07% |
719,478
-20,445
| -3% | -$897K |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q1 2018 Portfolio in Review
As of Q1 2018, Loomis, Sayles & Company held 967 positions worth $47.1B, down 1.9% from $48B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Loomis, Sayles & Company's Q1 2018 filing shows 122 new, 219 increased, 464 reduced and 97 closed positions. Its largest new stake was BioMarin Pharmaceuticals: 870,638 shares worth $70.6M. The largest sale was Amazon, an estimated $456M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q1 2018 buy was BioMarin Pharmaceuticals: 870,638 shares worth $70.6M.
- Loomis, Sayles & Company added most to Regeneron Pharmaceuticals in Q1 2018, an estimated $250M increase.
- Loomis, Sayles & Company's biggest Q1 2018 reduction was Amazon, cutting an estimated $456M.
- Loomis, Sayles & Company fully exited Analog Devices in Q1 2018, selling an estimated $151M.
- Loomis, Sayles & Company's ten largest holdings make up 35% of its $47.1B portfolio in Q1 2018.
- Loomis, Sayles & Company opened 122 new positions and closed 97 in Q1 2018.
- Loomis, Sayles & Company's portfolio value fell 1.9% quarter-over-quarter to $47.1B.
Based on Loomis, Sayles & Company's 13F filing for Q1 2018, filed 11 May 2018.